Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects-Reference-Cited by-同舟云学术

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects

Published:2011-05-24 Issue:7 Volume:13 Page:604-614
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:

Author:

Patel C. G.,Kornhauser D.,Vachharajani N.,Komoroski B.,Brenner E.,Handschuh del Corral M.,Li L.,Boulton D. W.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2011.01381.x/fullpdf

Reference29 articles.

1. Onglyza [package insert].

2. The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.;Zander;Diabetologia,2006

3. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.;Deacon;Diabetes Obes Metab,2007

4. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.;Rodbard;Endocr Pract,2009

5. Clinical overview of saxagliptin for Type 2 diabetes management.;Rosenstock;Exp Rev Endocrinol Metab,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Safety and Efficacy of Combining Saxagliptin and Pioglitazone Therapy in Streptozocin-Induced Diabetic Rats;Biomedicines;2023-12-13

2. A validated UHPLC-QTOF-MS method for quantification of metformin and teneligliptin in rat plasma: Application to pharmacokinetic interaction study;Journal of Pharmaceutical and Biomedical Analysis;2017-09

3. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor;Clinical Pharmacokinetics;2016-06-09

4. Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2016-02-29

5. Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs;Current Drug Metabolism;2015-12-10